{"id":37798,"date":"2020-05-14T08:32:03","date_gmt":"2020-05-14T08:32:03","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=37798"},"modified":"2020-05-15T02:57:05","modified_gmt":"2020-05-15T02:57:05","slug":"monoclonal-antibodies-identified-in-convalescent-plasma-covid-19","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/37798","title":{"rendered":"Monoclonal antibodies identified in convalescent plasma COVID-19"},"content":{"rendered":"<p><strong><span lang=\"EN-US\"><b><img loading=\"lazy\" decoding=\"async\" class=\" alignright\" src=\"https:\/\/i-base.info\/wp-content\/uploads\/2020\/03\/COVID-19-graphic.png\" width=\"231\" height=\"142\" \/><\/b><\/span>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Italian researchers from GSK report on isolation of broadly neutralising monoclonal antibodies from convalescent plasma that will be lead candidates as potential treatment for COVID-19.<\/strong><\/p>\n<p>This study, currently online before peer review, involved screening more than 1,100 memory B cells from seven people who had recovered from COVID-19 and incubating cells for two weeks to allow natural production of antibodies. Of these, 318 B cells expressed human monoclonal antibodies that inhibited the spike protein in vitro, 74 of which inhibited binding to receptors on Vero E6\u00a0 cells, and 17 neutralised CoV-2 in vitro.<\/p>\n<p>These will be studied as lead compounds for further development as potential treatments.<\/p>\n<p>Reference<\/p>\n<p>Andreano E et al. Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients. Published before peer review.<br \/>\n<a href=\"https:\/\/www.biorxiv.org\/content\/10.1101\/2020.05.05.078154v2\" rel=\"noopener noreferrer\">https:\/\/www.biorxiv.org\/content\/10.1101\/2020.05.05.078154v2<\/a><b><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Italian researchers from GSK report on isolation of broadly neutralising monoclonal antibodies from convalescent plasma that will be lead candidates as potential treatment for COVID-19. This study, currently online before peer review, involved screening more than &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[283,278],"tags":[],"class_list":["post-37798","post","type-post","status-publish","format-standard","hentry","category-covid-19-investigational-drugs","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/37798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=37798"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/37798\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=37798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=37798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=37798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}